UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBCGlobeNewsWire · 5 days ago
UroGen Pharma: An Emerging GARP StockSeeking Alpha · Oct 13, 2026
Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38 According to AnalystsDefense World · Oct 12, 2026
Here's Why You Should Add URGN Stock to Your Portfolio NowZacks Investment Research · Sep 30, 2026
Critical Analysis: Zoetis (NYSE:ZTS) and Urogen Pharma (NASDAQ:URGN)Defense World · Sep 10, 2026
Urogen Pharma: Upside After Bladder Cancer LaunchSeeking Alpha · Sep 9, 2026UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.27 | -$0.28 | Miss |
| May 6, 2026 | -$0.56 | -$0.47 | Beat |
| Mar 2, 2026 | -$0.52 | -$0.54 | Miss |
| Nov 6, 2025 | -$0.72 | -$0.69 | Beat |
| Aug 7, 2025 | -$0.82 | -$1.05 | Miss |
| May 12, 2025 | -$0.83 | -$0.92 | Miss |